SS Innovations Rings NASDAQ Bell

By Bobby Samwell • Monday, June 02 15:48 • Permanent Link

SS Innovations International, Inc. (NASDAQ: SSII) has announced that the company will ring the opening bell at the NASDAQ Marketsite in New York City on Tuesday, June 3, 2025. This event commemorates the uplisting of SS Innovations' common stock to NASDAQ in April 2025, a significant milestone for the company.

The company's Chairman of the Board and Chief Executive Officer, Dr. Sudhir Srivastava, highlighted the successful completion of more than 4,000 robotic surgeries by the SSI Mantra across over one hundred types of surgeries without any complications, injuries, or mortalities. This milestone was reached last month, demonstrating the reliability and safety of the SSI Mantra system.

Dr. Srivastava also expressed optimism about the growing acceptance of the SSI Mantra among physicians across India and in six other countries. The company remains on track to introduce the system in new markets around the world, including the European Union and the United States.

SS Innovations aims to enable advanced, accessible, and affordable robotic surgery for a broader segment of patients in need through the global deployment of the SSI Mantra.

The company's live broadcast of the NASDAQ opening bell ceremony will begin at 9:15 a.m. Eastern Time and will be available for viewing, along with a replay of the event.

SS Innovations International, Inc. develops innovative surgical robotic technologies, including its proprietary "SSI Mantra" surgical robotic system and its comprehensive suite of "SSI Mudra" surgical instruments. The company plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. As a result of these announcements, the company's shares have moved 1.11% on the market, and are now trading at a price of $6.40. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.